The rising prevalence of diseases in both developed and developing nations highlights the need to explore new pharmaceutical ...
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results